Acute Kidney Injury Pipeline 2025: Clinical Trials Overview, MOA, and ROA Insights by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Kidney Injury pipeline constitutes 30+ key companies continuously working towards developing 30+ Acute Kidney Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Kidney Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Acute Kidney Injury Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Kidney Injury Market.

Some of the key takeaways from the Acute Kidney Injury Pipeline Report: https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Acute Kidney Injury treatment therapies with a considerable amount of success over the years.
• Acute Kidney Injury companies working in the treatment market are Revelation Biosciences, RegeneRx Biopharmaceuticals, MISSION Therapeutics, Unicycive Therapeutics, Sentien Biotechnologies, Metro International Biotech, Guard Therapeutics AB, Novartis, Angion Biomedica/Vifor, AM Pharma, Astellas Pharma, Pharming Technologies, RegeneRx Biopharmaceuticals, and others, are developing therapies for the Acute Kidney Injury treatment
• Emerging Acute Kidney Injury therapies in the different phases of clinical trials are- REVTx-300, RGN-352, MTX652, UNI-494, SBI-101, MIB-626, RMC-035, TIN816, ANG-3777, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), Timbetasin, and others are expected to have a significant impact on the Acute Kidney Injury market in the coming years.
• In January 2025, SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company focused on innovative treatments to mitigate the impact of hyperinflammation on vital organs, has announced that Mayo Clinic has received clearance to enroll participants in its NEUTRALIZE-AKI pivotal trial, bringing the total number of active trial sites to 15.
• In October 2024, Unicycive Therapeutics reported encouraging outcomes from its Phase I clinical trial of UNI-494, a patented pro-drug of nicorandil currently being developed for acute kidney injury (AKI). The study demonstrated that UNI-494 was safe and well-tolerated across both single and multiple ascending dose groups. Additionally, the drug exhibited rapid absorption and metabolism, with plasma concentrations rising proportionally with higher doses.
• In January 2024, Renibus Therapeutics released findings from a Phase II Study investigating RBT-1 as a preoperative treatment to decrease complications after cardiothoracic surgery.


Acute Kidney Injury Overview
Acute Kidney Injury (AKI), formerly known as acute renal failure, is a sudden and rapid decline in kidney function. This condition is characterized by a sudden and significant decrease in the kidneys' ability to filter and eliminate waste products and excess fluids from the blood. Acute Kidney Injury can occur over a few hours or days, and it is often reversible with appropriate and timely treatment.

Get a Free Sample PDF Report to know more about Acute Kidney Injury Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Acute Kidney Injury Drugs Under Different Phases of Clinical Development Include:
• REVTx-300: Revelation Biosciences
• RGN-352: RegeneRx Biopharmaceuticals
• MTX652: MISSION Therapeutics
• UNI-494 Unicycive Therapeutics
• SBI-101 Sentien Biotechnologies
• MIB-626 Metro International Biotech
• RMC-035 Guard Therapeutics AB
• TIN816 Novartis Pharmaceuticals
• ANG-3777: Angion Biomedica/Vifor
• Ilofotase alfa: AM Pharma
• ASP1128: Astellas Pharma
• Ruconest (Conestat alfa): Pharming Technologies
• RMC-035: Guard Therapeutics
• SBI-101: Sentien Biotechnologies
• Timbetasin: RegeneRx Biopharmaceuticals

Acute Kidney Injury Route of Administration
Acute Kidney Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Acute Kidney Injury Molecule Type
Acute Kidney Injury Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Acute Kidney Injury Pipeline Therapeutics Assessment
• Acute Kidney Injury Assessment by Product Type
• Acute Kidney Injury By Stage and Product Type
• Acute Kidney Injury Assessment by Route of Administration
• Acute Kidney Injury By Stage and Route of Administration
• Acute Kidney Injury Assessment by Molecule Type
• Acute Kidney Injury by Stage and Molecule Type

DelveInsight's Acute Kidney Injury Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Acute Kidney Injury product details are provided in the report. Download the Acute Kidney Injury pipeline report to learn more about the emerging Acute Kidney Injury therapies
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Acute Kidney Injury Therapeutics Market include:
Key companies developing therapies for Acute Kidney Injury are - Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, Nephraegis Therapeutics, Vasomune, Unicycive, ABIONYX and others.

Acute Kidney Injury Pipeline Analysis:
The Acute Kidney Injury pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Kidney Injury with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Kidney Injury Treatment.
• Acute Kidney Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Kidney Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Kidney Injury market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Kidney Injury drugs and therapies
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Kidney Injury Pipeline Market Drivers
• Rising incidence of Acute Kidney injuries, the rising geriatric population are some of the important factors that are fueling the Acute Kidney Injury Market.

Acute Kidney Injury Pipeline Market Barriers
• However, side-effects associated with the treatment, lack of awareness and other factors are creating obstacles in the Acute Kidney Injury Market growth.

Scope of Acute Kidney Injury Pipeline Drug Insight
• Coverage: Global
• Key Acute Kidney Injury Companies: Revelation Biosciences, RegeneRx Biopharmaceuticals, MISSION Therapeutics, Unicycive Therapeutics, Sentien Biotechnologies, Metro International Biotech, Guard Therapeutics AB, Novartis, Angion Biomedica/Vifor, AM Pharma, Astellas Pharma, Pharming Technologies, RegeneRx Biopharmaceuticals, and others
• Key Acute Kidney Injury Therapies: REVTx-300, RGN-352, MTX652, UNI-494, SBI-101, MIB-626, RMC-035, TIN816, ANG-3777, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), Timbetasin, and others
• Acute Kidney Injury Therapeutic Assessment: Acute Kidney Injury current marketed and Acute Kidney Injury emerging therapies
• Acute Kidney Injury Market Dynamics: Acute Kidney Injury market drivers and Acute Kidney Injury market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.